Navigation Links
Galectin Therapeutics Exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV
Date:12/2/2013

(PRWEB) December 02, 2013

Galectin Therapeutics was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Marina Del Rey, California.

During the interview Galectin Therapeutics Executive Chairman, Jim Czirr, said "Galectin Therapeutics is a pharmaceutical company. We are working on drugs to treat untreatable disease at the moment. Diseases like nash, fatty liver disease with fibrosis, cirrhosis of the liver, as well as cancer. This protein called galectin is implicated in those diseases and is responsible for the advancement of the diseases. By inhibiting them or by blocking them we are able to affect the disease in a positive way and improve the patient’s life. In the case of fibrosis, we have evidence that we can reverse it, in the case of cancer, we show great improvement in immune system function with our product."

The interview was conducted by FSXinterlinked Investment Conference Host, Michael Fugler, and is available on the FSXinterlinked channel on InterlinkedTV and more information is available at Galectin Therapeutics’ website.

Galectin Therapeutics, formerly Pro-Pharmaceuticals, is a development-stage company, engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases.

About FSXinterlinked Investment Conference
FSXinterlinked is the premier investment conference organization in the United States. Founded as Financial Services Exchange (FSX) in 1983, it is a national organization comprised of independent FINRA broker/dealer firms and private equity fund managers. With quarterly investment conferences hosted throughout the U.S., FSXinterlinked creates a forum for emerging growth companies seeking capital to present to a nationwide network of financial investment professionals.

The FSXinterlinked network of independent broker/dealers has a combined sales force of thousands of accredited investors looking to invest in companies of all sizes and industries. To date, more than $3 billion has been raised for presenting companies through the FSXinterlinked network. FSXinterlinked’s exclusive network of FINRA firms makes the investment conferences the ideal setting for private and public companies seeking mezzanine financing, funding for private placements, IPOs, secondary financing and pipes, exposure, and more. For more information, visit http://www.fsxinterlinked.com/.

Interlinked is a global investment community of accredited investors, emerging growth companies, and resource partners. Interlinked offers an efficient way for companies to maximize exposure and access a private network of funding sources and verified service providers. For investors, Interlinked provides a secure environment to find, vet and engage companies, and communicate with members. Interlinked gives members exclusive access to a proprietary investment platform, which integrates virtual data rooms, video news, a service provider marketplace, an event directory, and customized marketing services, including email marketing, video production, public relations and more. For more information, visit: http://www.interlinked.com/.

Safe Harbor Statement
This press release may contain information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11377501.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
3. FORMA Therapeutics teams with TGen Drug Development
4. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
5. Research shows potential of microneedles to target therapeutics to the back of the eye
6. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
10. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
11. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: